Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation

Cancer

Volumn 118, Issue 15, 2012, Pages 3801-3811

  Wang, Jiansheng ^a,b   Estrella, Jeannelyn S ^a   Peng, Lan ^a   Rashid, Asif ^a   Varadhachary, Gauri R ^a   Wang, Hua ^a   Lee, Jeffrey E ^a   Pisters, Peter W T ^a   Vauthey, Jean Nicolas ^a   Katz, Matthew H ^a   Gomez, Henry F ^a   Evans, Douglas B ^c   Abbruzzese, James L ^a   Fleming, Jason B ^a   Wang, Huamin ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

pancreatic adenocarcinoma; portal vein; prognosis; superior mesenteric vein; survival

Indexed keywords

CISPLATIN; FLUOROPYRIMIDINE; GEMCITABINE;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CHOLECYSTECTOMY; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PORTAL VEIN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SUPERIOR MESENTERIC VEIN; VASCULAR TUMOR; VEIN SURGERY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MESENTERIC ARTERY, SUPERIOR; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PORTAL VEIN; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84864144630     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26717     Document Type: Article

References (32)

1. Fortner JG,. Regional resection of cancer of the pancreas: a new surgical approach. Surgery. 1973; 73: 307-320.
2. Takahashi S, Ogata Y, Tsuzuki T,. Combined resection of the pancreas and portal vein for pancreatic cancer. Br J Surg. 1994; 81: 1190-1193.
3. Allema JH, Reinders ME, van Gulik TM, et al. Portal vein resection in patients undergoing pancreatoduodenectomy for carcinoma of the pancreatic head. Br J Surg. 1994; 81: 1642-1646.
4. Tseng JF, Raut CP, Lee JE, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg. 2004; 8: 935-949; discussion 949-950.
5. Harrison LE, Klimstra DS, Brennan MF,. Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection? Ann Surg. 1996; 224: 342-347; discussion 347-349.
6. Raut CP, Tseng JF, Sun CC, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007; 246: 52-60.
7. Ramacciato G, Mercantini P, Petrucciani N, et al. Does portal-superior mesenteric vein invasion still indicate irresectability for pancreatic carcinoma? Ann Surg Oncol. 2009; 16: 817-825.
8. Abrams RA, Lowy AM, O'Reilly EM, Wolff RA, Picozzi VJ, Pisters PW,. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 2009; 16: 1751-1756.
9. Katz MH, Merchant NB, Brower S, et al. Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial. Ann Surg Oncol. 2011; 18: 337-344.
10. Chua TC, Saxena A,. Extended pancreaticoduodenectomy with vascular resection for pancreatic cancer: a systematic review. J Gastrointest Surg. 2010; 14: 1442-1452.
11. Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A, eds. AJCC Cancer Staging Manual. New York, NY: Springer; 2010.
12. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26: 3496-3502.
13. Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26: 3487-3495.
14. Bold RJ, Charnsangavej C, Cleary KR, et al. Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis. J Gastrointest Surg. 1999; 3: 233-243.
15. Evans DB, Farnell MB, Lillemoe KD, Vollmer C Jr, Strasberg SM, Schulick RD,. Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 2009; 16: 1736-1744.
16. Nakagohri T, Kinoshita T, Konishi M, Inoue K, Takahashi S,. Survival benefits of portal vein resection for pancreatic cancer. Am J Surg. 2003; 186: 149-153.
17. Shimada K, Sano T, Sakamoto Y, Kosuge T,. Clinical implications of combined portal vein resection as a palliative procedure in patients undergoing pancreaticoduodenectomy for pancreatic head carcinoma. Ann Surg Oncol. 2006; 13: 1569-1578.
18. Kurosaki I, Hatakeyama K, Minagawa M, Sato D,. Portal vein resection in surgery for cancer of biliary tract and pancreas: special reference to the relationship between the surgical outcome and site of primary tumor. J Gastrointest Surg. 2008; 12: 907-918.
19. Hartel M, Niedergethmann M, Farag-Soliman M, et al. Benefit of venous resection for ductal adenocarcinoma of the pancreatic head. Eur J Surg. 2002; 168: 707-712.
20. Kawada M, Kondo S, Okushiba S, Morikawa T, Katoh H,. Reevaluation of the indications for radical pancreatectomy to treat pancreatic carcinoma: is portal vein infiltration a contraindication? Surg Today. 2002; 32: 598-601.
21. Riediger H, Makowiec F, Fischer E, Adam U, Hopt UT,. Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection. J Gastrointest Surg. 2006; 10: 1106-1115.
22. Muller SA, Hartel M, Mehrabi A, et al. Vascular resection in pancreatic cancer surgery: survival determinants. J Gastrointest Surg. 2009; 13: 784-792.
23. Shibata C, Kobari M, Tsuchiya T, et al. Pancreatectomy combined with superior mesenteric-portal vein resection for adenocarcinoma in pancreas. World J Surg. 2001; 25: 1002-1005.
24. Capussotti L, Massucco P, Ribero D, Vigano L, Muratore A, Calgaro M,. Extended lymphadenectomy and vein resection for pancreatic head cancer: outcomes and implications for therapy. Arch Surg. 2003; 138: 1316-1322.
25. Howard TJ, Villanustre N, Moore SA, et al. Efficacy of venous reconstruction in patients with adenocarcinoma of the pancreatic head. J Gastrointest Surg. 2003; 7: 1089-1095.
26. Poon RT, Fan ST, Lo CM, et al. Pancreaticoduodenectomy with en bloc portal vein resection for pancreatic carcinoma with suspected portal vein involvement. World J Surg. 2004; 28: 602-608.
27. Zhou GW, Wu WD, Xiao WD, Li HW, Peng CH,. Pancreatectomy combined with superior mesenteric-portal vein resection: report of 32 cases. Hepatobiliary Pancreat Dis Int. 2005; 4: 130-134.
28. Jain S, Sacchi M, Vrachnos P, Lygidakis NJ,. Carcinoma of the pancreas with portal vein involvement-our experience with a modified technique of resection. Hepatogastroenterology. 2005; 52: 1596-1600.
29. Al-Haddad M, Martin JK, Nguyen J, et al. Vascular resection and reconstruction for pancreatic malignancy: a single center survival study. J Gastrointest Surg. 2007; 11: 1168-1174.
30. Chakravarty KD, Hsu JT, Liu KH, et al. Prognosis and feasibility of en-bloc vascular resection in stage II pancreatic adenocarcinoma. World J Gastroenterol. 2010; 16: 997-1002.
31. Fukuda S, Oussoultzoglou E, Bachellier P, et al. Significance of the depth of portal vein wall invasion after curative resection for pancreatic adenocarcinoma. Arch Surg. 2007; 142: 172-179; discussion 180.
32. Nakao A, Harada A, Nonami T, Kaneko T, Inoue S, Takagi H,. Clinical significance of portal invasion by pancreatic head carcinoma. Surgery. 1995; 117: 50-55.